Your browser doesn't support javascript.
loading
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes.
Rivera, Daniel; Kim, Kunhwa; Kanagal-Shamanna, Rashmi; Borthakur, Gautam; Montalban-Bravo, Guillermo; Daver, Naval; Dinardo, Courtney; Short, Nicholas J; Yilmaz, Musa; Pemmaraju, Naveen; Takahashi, Koichi; Jabbour, Elias J; Pierce, Sherry; Konopleva, Marina; Bhalla, Kapil; Garcia-Manero, Guillermo; Ravandi, Farhad; Kantarjian, Hagop; Kadia, Tapan M.
Affiliation
  • Rivera D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kim K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Dinardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Bhalla K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Am J Hematol ; 97(12): 1599-1606, 2022 12.
Article in En | MEDLINE | ID: mdl-36117258
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Am J Hematol Year: 2022 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: En Journal: Am J Hematol Year: 2022 Document type: Article Affiliation country: United States Country of publication: United States